See the DrugPatentWatch profile for januvia
What is the generic name for Januvia?
The generic name for Januvia is sitagliptin [1].
When is sitagliptin expected to become available as a generic?
The U.S. patent for Januvia is set to expire in 2026 [2]. This means that generic versions of sitagliptin could become available around that time, pending any successful patent challenges or extensions.
What is sitagliptin used for?
Sitagliptin is used to treat type 2 diabetes by helping to lower blood sugar levels. It works by increasing the levels of incretin hormones, which stimulate the pancreas to release more insulin and reduce the amount of sugar the liver produces [3].
How does sitagliptin work in the body?
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor [3]. DPP-4 is an enzyme that breaks down incretin hormones. By inhibiting DPP-4, sitagliptin increases the levels of active incretin hormones, such as GLP-1 and GIP. These hormones then signal the pancreas to release more insulin when blood sugar is high and reduce the release of glucagon, which raises blood sugar [3].
Are there any alternatives to Januvia for type 2 diabetes treatment?
Yes, there are several other classes of medications for type 2 diabetes, including metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, and GLP-1 receptor agonists. The best option depends on individual patient factors such as kidney function, cardiovascular risk, and other medical conditions [4].
What are the common side effects of sitagliptin?
Common side effects of sitagliptin include upper respiratory tract infection, headache, and nausea [3]. More serious but rare side effects can include pancreatitis, severe joint pain, and hypoglycemia (low blood sugar) when used in combination with other diabetes medications [3].
What is the typical cost of Januvia and what might generic sitagliptin cost?
The cost of brand-name Januvia can vary significantly depending on insurance coverage and pharmacy. Once generic sitagliptin becomes available, its price is generally expected to be lower than the brand-name version. Specific pricing for generic sitagliptin will depend on market competition and manufacturer pricing at the time of launch [5].
Who are the major manufacturers involved with Januvia and its potential generics?
Merck & Co. is the original manufacturer of Januvia. As the patent approaches expiration, other pharmaceutical companies will likely seek to manufacture and market generic versions of sitagliptin. Information on companies seeking FDA approval for generic sitagliptin can often be found on regulatory websites and patent tracking resources such as DrugPatentWatch.com [6].
What is the patent situation for Januvia (sitagliptin)?
The primary U.S. patent for Januvia is expected to expire in 2026 [2]. However, drug patents can be complex, and there may be other related patents covering different aspects of the drug, such as manufacturing processes or formulations. Patent litigation is common in the pharmaceutical industry, and challenges to these patents can sometimes lead to earlier generic entry [6].
Sources:
[1] https://www.webmd.com/drugs/2/200613/sitagliptin-oral
[2] https://www.drugpatentwatch.com/drug/januvia
[3] https://www.mayoclinic.org/drugs-supplements/sitagliptin-oral-route/proper-use/drg-20070733
[4] https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/type-2-diabetes/treatment
[5] https://www.goodrx.com/januvia
[6] https://www.drugpatentwatch.com/